Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection

The persistent mutation of the novel coronavirus (SARS-CoV-2) not only remains a threat to human health but also continues to challenge existing antiviral therapeutic strategies. In current clinical practice, the resistance of novel coronavirus to antivirals, the rebound of viral load after treatment with drugs such as nirmatrelvir/ritonavir (NTV/r), and the urgent need for rapid clearance of the virus in the management of critically and emergently ill patients suggest that the existing single-drug regimens may have limitations and that the intensity of suppression may be insufficient in some cases. In clinical practice, we have observed that a combination of antivirals with different mechanisms of action can result in better efficacy and not significantly increase adverse drug reactions (ADRs). For some immunosuppressed, post-transplantation, or other special patients in particular, such as those in whom COVID-19 nucleic acids tended not to be negative after conventional treatment, when virus clearance is still the main goal, the combination of small-molecule antivirals can help to clear the virus as early as possible and attempt to improve the success rate of salvage. Based on evidence-based medicine and in light of the current situation of China, we assembled experts from disciplines such as infectious diseases, respiratory medicine, critical care medicine, and clinical pharmacy into a group to carry out a systematic literature search and identify key issues and to put forward relevant recommendations to reach an Expert Consensus on Combined Use of Oral Small-molecule Antivirals to Treat COVID-19, which is intended to serve as a reference for clinical practice.

Authors

Institutions

Publication Details

Journal
BioScience Trends
Published
2025-08-25
DOI
https://doi.org/10.5582/bst.2025.01244
Citations
1
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
1.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection

Liuqing Yang, Yue Wei, Bingliang Lin, Bo Qin et al.
1 citations
BioScience Trends
Influenza Virus Research Studies
1.35
article

Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection

Liuqing Yang, Yue Wei, Bingliang Lin, Bo Qin, Yutian Chong, Zhijun Qu, Weizhen Weng, Hailin Yu, Jia Huang, Zuojiong Gong, Kaijin Xu, Xinru Li, Jing Yuan, Xiaomei Lai, Kun Qiao, CuiQing Liu, Cheng-hui Huang, Zhuguo Wu, Xilong Deng, Yanfen Wu, Conglin Ye, Yizhang Zheng, Yuan Gao, Liang Fu, Tao Wu, Zhongjie Hu, Yehong Sun, Wen Li, Xi Liu, Jie Peng, Junhao Zhang, Hongzhou Lu, Yana Xu, Feng Lin, Qian Zhang, Xiaojuan Yang, Haixia Sun, Guangbin Chen, Gang Wu, Yongfang Jiang, Lin Mao, Jun Chen, X. Li, Wen‐Jing Qian, Bin Liu
article en
1 citations

Abstract

The persistent mutation of the novel coronavirus (SARS-CoV-2) not only remains a threat to human health but also continues to challenge existing antiviral therapeutic strategies. In current clinical practice, the resistance of novel coronavirus to antivirals, the rebound of viral load after treatment with drugs such as nirmatrelvir/ritonavir (NTV/r), and the urgent need for rapid clearance of the virus in the management of critically and emergently ill patients suggest that the existing single-drug regimens may have limitations and that the intensity of suppression may be insufficient in some cases. In clinical practice, we have observed that a combination of antivirals with different mechanisms of action can result in better efficacy and not significantly increase adverse drug reactions (ADRs). For some immunosuppressed, post-transplantation, or other special patients in particular, such as those in whom COVID-19 nucleic acids tended not to be negative after conventional treatment, when virus clearance is still the main goal, the combination of small-molecule antivirals can help to clear the virus as early as possible and attempt to improve the success rate of salvage. Based on evidence-based medicine and in light of the current situation of China, we assembled experts from disciplines such as infectious diseases, respiratory medicine, critical care medicine, and clinical pharmacy into a group to carry out a systematic literature search and identify key issues and to put forward relevant recommendations to reach an Expert Consensus on Combined Use of Oral Small-molecule Antivirals to Treat COVID-19, which is intended to serve as a reference for clinical practice.

BioScience TrendsVol. 19(5)
Central South University (CN), Sun Yat-sen University (CN), Guangdong Medical College (CN), Wuhan University (CN), Affiliated Hospital of Southwest Medical University (CN), Nanfang Hospital (CN), Fifth Affiliated Hospital of Sun Yat-sen University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Renmin Hospital of Wuhan University (CN), Third Affiliated Hospital of Sun Yat-sen University (CN), Second Xiangya Hospital of Central South University (CN), Southern Medical University (CN), Chongqing Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 16%
Influenza Virus Research Studies
1.35
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.